

# NEW FROM WILLACH

## CONSIS.ATP pouch packagers



**Super fast. Accurate. Expandable. Versatile.**

Efficiency, reliability and superior customer support to grow your DAA business - from Willach  
**Australia's trusted leader in pharmacy solutions.**



**CONSIS.ATP mini**

Speed:	Up to 60 pouches/min
Capacity:	64 - 192 canisters
Footprint:	0.89 m <sup>2</sup>



**CONSIS.ATP 2**

Speed:	Up to 60 pouches/min
Capacity:	256 - 480 canisters
Footprint:	0.89 - 1.36 m <sup>2</sup>

**Grow your DAA business - talk to Willach**



## Today's issue of PD

Pharmacy Daily today has two pages of news plus a front cover wrap from Willach and the MIMS Monthly Update.

## Fake cancer therapist

**THE** Australian Health Practitioner Regulation Agency (AHPRA) has uncovered a scam by a person allegedly claiming to be able to cure cancers and using testimonials in his advertising.

The Downing Centre Local Court in Sydney found registered Chinese medicine practitioner Qi Xin Chen guilty of 30 charges filed by AHPRA.

Chen, the man behind the Australian Natural Medicine Center, was convicted of false, misleading or deceptive advertising through the publication on his websites of several articles about the treatment of cancer and other illnesses.

Such advertising "is prohibited under the National Law and would have created for consumers an unreasonable expectation of beneficial treatment," the court ruled.

Chinese Medicine Board of Australia Chair, Professor Charlie Xue said practitioners would be held accountable under the National Law for this kind of flagrant misuse of advertising.

Chen was fined \$1,500 per offence, totalling \$45,000, by the Court and was also ordered to pay \$5,000 towards AHPRA's legal costs.

AHPRA CEO Martin Fletcher welcomed today's outcome "which sends an important message".

Visit [ahpra.gov.au](http://ahpra.gov.au) for the ruling.

## Rocket under MedAdvisor

**LISTED** medication adherence technology firm MedAdvisor has been recognised as one of Australia's fastest growing companies, with revenue increasing on an average annual rate of 84.8% over the last three years.

The company has been included in the *Australian Financial Review* "Fast 100 Companies" list released

## VPA consultation rooms update

**THE** Victorian Pharmacy Authority has released the final version of its new guidelines, after a public consultation which has seen it make adjustments to requirements around consultation rooms and immunisation rooms in pharmacies.

The revised guidelines, which became effective yesterday, are available at [pharmacy.vic.gov.au](http://pharmacy.vic.gov.au).

A communiqué issued yesterday also confirmed changes to the public register on the VPA website, which includes details of all licensees and registered premises.

The update has improved the visibility of all conditions, including administrative items such as transitional conditions imposed on a new licence or registration now being displayed.

**MEANWHILE** recent panel hearings detailed included a case of security failures in a relocated pharmacy where upstairs windows were vulnerable and no lockable roller shutter was installed.

In addition a Schedule 8 drug safe was not adequately secured.

**CRAMPEZE GEL**

Can be used in combination with Crampeze Night Cramps or Crampeze Forte

Crampeze® Gel contains ingredients traditionally used in aromatherapy and western herbal medicine to relieve:

- MUSCLE CRAMPS
- JOINT PAINS AND SORENESS
- MUSCLE ACHES
- MILD RHEUMATIC PAIN

Always read the label and use only as directed. If symptoms persist, consult your healthcare professional.

## Willach DAA solution

**WILLACH** is today highlighting this week's Australian launch of CON.SIS.ATP pouch packagers, which provide pharmacies with an innovative way to grow their Dose Administration Aids business.

There are two systems available: the CON.SIS.ATP mini which can pack up to 40 pouches per minute from a range of 64-192 canisters, and the larger CON.SIS.ATP 2 which has capacity for up to 60 pouches per minute from 256-480 canisters.

Each pouch is customised with medication for an individual patient sorted by day and time of medication intake.

See the **cover page** for details.

## Rubella officially gone

**MINISTER** for Health Greg Hunt has announced that Rubella, aka German measles, is officially "eliminated" from Australia, according to World Health Organization (WHO) standards.

Last month Hunt announced the nation-wide immunisation rates for five year olds had reached 94.62%, the highest figure on record.

"I commend the efforts of Australia's health professionals over the decades and the millions of parents who ensure their children are always vaccinated," Hunt said.

"Our National Immunisation Program played an essential role in this huge achievement by ensuring high levels of vaccination coverage for rubella."

Recent legislation has broadened access to measles/mumps/rubella vaccination via readily accessible pharmacies.

## PPA legal webinar

**PROFESSIONAL** Pharmacists Australia (PPA) has announced a webinar training program for members on Understanding Awards and Agreements.

Professionals Australia National Industrial Officer and Lawyer Deepa Travers outlines "everything you need to know" - for details see [professionalpharmacists.com.au](http://professionalpharmacists.com.au).

Your Pharmacy Recruitment Experts

**Raven's recruitment**

FreeCall: 1800 429 829  
Email: [info@ravensrecruitment.com.au](mailto:info@ravensrecruitment.com.au)  
Web: [www.ravensrecruitment.com.au](http://www.ravensrecruitment.com.au)

### Jobs of the Week

- Pharmacist** - Mid East Coast, NSW (Job# 200031043)  
Positive team environment + great hourly rate + neg benefits.
- Pharmacist in Charge** - Mt Gambier, SA (Job# 200031328)  
Benefits incl accom, Domestic flights home each quarter + Great \$\$
- Pharmacist in Charge** - Rockhampton, QLD (Job# 200030949)  
Fresh pharmacy with great support and high hourly rate - 5 day week!

Looking for a different direction for your career? We can help!

\*IRI MarketEdge, Hand products, unit sales - Chemist Warehouse, MAT 28/1/18

**DU'IT**

**SOFTENS REPAIRS & PROTECTS**

DRY, ROUGH, CALLOUSED AND IRRITATED HANDS.

**TOUGH HANDS**  
INTENSIVE SKIN REPAIR  
FOR DRY, CRACKED & IRRITATED HANDS

150g

- Antimicrobial
- Non-greasy
- Protective barrier
- Diabetic friendly
- No Petroleum, Parabens
- No Mineral Oil
- Results within 5 days
- Australian Made

Call HealthOne 02 9965 9600

FIND OUT MORE >

Stay up to date  
on the go

Download the app



Pharmacy Daily



## Dispensary Corner

**ICONIC** Australian foods have been subject to significant humiliation in a new tourist attraction in Sweden.

Labelled the Disgusting Food Museum, three star-attractions including our own Vegemite, witchetty grubs and musk sticks - all earned a spot on the dubious podium of shame.

Other products to make the unenviable cut included Twinkies from the USA, a boiled duck egg with a partially developed foetus from the Philippines, haggis from Scotland, pork brains from the USA and casu marzu — maggot-infested cheese — from Sardinia.

And more: baby mice wine from China, fruit bat soup from Guam (pictured), and rotting century eggs from China.

Mmmm, is it lunch-time yet?



**NOW** that's a relief!

Remember that recent stolen inflatable colon story (PD 24 Oct)?

Kansas police have found it after being tipped off about its location in an abandoned house - it had been stolen from the back of a truck much to the despair of the university cancer research centre using it in a health promotion: "Get Your Rear in Gear".

The good news is that public donations flooded in to pay for two more inflatable colons.

Twitter storm: "Grammar police have solved the case of the missing colon." "Phew, just in time for the elections!" & more.

## Sigma sleep apnoea triumph

**SIGMA'S** Amcal and Guardian branded pharmacies are celebrating the success of the first six months of their national sleep apnoea program, which has seen a significant lift in program uptake and specialist referrals.

Amcal and Guardian Retail GM Brian Tomlin said the Sigma partnership with Philips offshoot Australian Pharmacy Sleep Services (APSS) (PD 03 May 2018) had created the nation's largest sleep apnoea network.

Tomlin added that the support received from APSS, including extensive pharmacist training and additional in-store pharmacy support, had contributed greatly to the successful roll out.

"With the assistance of APSS approximately 175 stores nationwide now offer this industry-leading service, with an additional 25 set to offer the program in the coming months," Tomlin said.

"Additionally, since Aug 2018, all sleep studies from those 175 who have undertaken the program have had their sleep studies assessed

by Dr Donald Lee, Sleep Physician of Nepean Lung and Sleep, who reports on behalf of APSS."

Tomlin said the pharmacies continued to act as a "trusted and experienced first point of contact" on how Australians can manage symptoms of sleep apnoea and help to get a better night's sleep.

For more information on the program see [amcal.com.au](http://amcal.com.au).

## Priceline Pops recall



**MY LITTLE** Pony and Avengers Giant Pops (pictured) are being urgently recalled by Food Standards Australia & NZ (FSANZ) because the products potentially contain metal.

Made in China and distributed by Park Avenue Foods, the items were sold in Priceline Pharmacies nationally in time for Halloween.

FSANZ said they should not be eaten but returned for a refund.

## Win with SkinB5

This week **Pharmacy Daily** & **SkinB5** are giving away each day the NEW SkinB5's Clear Skin Superfood Booster valued at \$63.90.

Specifically formulated for acne / blemish prone skin, SkinB5's Clear Skin Superfood Booster delivers over 63 key skin health ingredients including Vitamins B5, A, C, D, E, minerals, essential fatty acids, amino acids, digestive enzymes, probiotics and prebiotics, Marine Collagen, Australian Organic Hemp protein, Organic Zinc, Maca, probiotics, prebiotics, Turmeric, Ginseng, Ashwaganda, Alkalisng Greens and colourful super fruits. Follow [www.facebook.com/skinb5pro](http://www.facebook.com/skinb5pro) for more. Available through Sigma - PDE 301911.

To win, be the first person from VIC or TAS to send the correct answer to [comp@pharmacydaily.com.au](mailto:comp@pharmacydaily.com.au)



What ingredient do you need for Harmonising, cleansing & chi-promoting herbs starting with "M"?

Check here tomorrow for today's winner

## Child antibiotic obesity

**YOUNG** children prescribed antibiotics may be at heightened risk of obesity, according to research published in *Gut*.

These drugs, particularly if taken for lengthy periods, may enhance gut microbes that have been associated with weight gain, researchers explained.

Other drugs, such as histamine H2 receptor antagonists and proton pump inhibitors have also been associated with these effects.

Researchers concluded antibiotics were associated with a 26% heightened risk of obesity.

**CLICK HERE** to access the study.



## Events Calendar

**WELCOME** to **Pharmacy Daily's** events calendar, opportunities to earn CPE and CPD points.

If you have an upcoming event you'd like us to feature, email [info@pharmacydaily.com.au](mailto:info@pharmacydaily.com.au).

**22 - 25 Nov:** SHPA Medicines Management 2018; Brisbane Convention & Exhibition Centre; register here: [www.mm2018shpa.com](http://www.mm2018shpa.com)

**27-30 Nov:** ASCEPT 2018 Annual Scientific Meeting; Adelaide Convention Centre; for details visit: [www.asceptasm.com](http://www.asceptasm.com)

**22 - 28 Jan:** NAPSA Congress; University of South Australia, Adelaide; for more info see: [www.napsacongressadelaide19.com](http://www.napsacongressadelaide19.com)

**7 - 10 Mar:** APP 2019; Gold Coast Convention and Exhibition Centre; early bird registration now open: [www.appconference.com](http://www.appconference.com)

## New Products

- Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy)** contains the new integrase strand transfer inhibitor (INSTI) bictegravir, that binds to the integrase active site and blocks the strand transfer step of retroviral DNA integration which is essential for the HIV replication cycle. Bictegravir has activity that is specific to HIV-1 and HIV-2. Biktarvy is indicated for the treatment of HIV-1 infection in adults who are antiretroviral therapy naïve or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA < 50 copies per mL) on a stable antiretroviral regimen at the start of therapy with no history of treatment failure, and no known substitutions associated with resistance to the individual components of Biktarvy. Biktarvy is contraindicated with coadministration of dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life threatening events. Coadministration with rifampicin is contraindicated due to decreased bictegravir plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to Biktarvy. Biktarvy tablets contain bictegravir 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 25 mg and are available in a pack size of 30.
- Emicizumab (rch) (Hemlibra)** is a humanised modified IgG4 monoclonal antibody with a bispecific antibody structure bridging factor IXa and factor X. Hemlibra bridges activated factor IX and factor X to restore the function of missing activated factor VIII (FVIII) that is needed for effective haemostasis. Prophylactic therapy with Hemlibra shortens the activated partial thromboplastin time (aPTT) and increases the reported FVIII activity. Emicizumab has no structural relationship or sequence homology to FVIII and, as such, does not induce or enhance the development of direct inhibitors to FVIII. Hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adult and paediatric patients with haemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. Hemlibra should be initiated under the supervision of a physician experienced in the treatment of haemophilia and/or bleeding disorders. Hemlibra is contraindicated in patients with known hypersensitivity to hamster derived proteins. Hemlibra solution for subcutaneous injection containing emicizumab 30 mg/mL (30 mg/1 mL) or 150 mg/mL (60 mg/0.4 mL, 105 mg/0.7 mL, 150 mg/1 mL) is available in a pack size of 1.
- Ertugliflozin/metformin hydrochloride (Segluromet)** combines two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride, a member of the biguanide class. Ertugliflozin displays > 2200-fold selectivity for SGLT2 (responsible for glucose reabsorption in the kidney) over SGLT1 (responsible for glucose absorption in the gut). Segluromet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. Segluromet is contraindicated with the following: moderate or severe renal impairment (eGFR < 60 mL/min/1.73 m<sup>2</sup>); acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma; acute conditions with the potential to alter renal function, such as dehydration, severe infection, shock or intravascular administration of iodinated contrast agents; acute or chronic disease which may cause tissue hypoxia, such as cardiac or respiratory failure, pulmonary embolism, recent myocardial infarction, shock, acute significant blood loss, sepsis, gangrene, pancreatitis; during or immediately following surgery where insulin is essential; due to metformin component, conditions that can lead to severe hepatic insufficiency, such as acute alcohol intoxication or alcoholism. Segluromet tablets are available in the following strengths: Segluromet 2.5/500 (ertugliflozin 2.5 mg, metformin hydrochloride 500 mg), Segluromet 2.5/1000 (ertugliflozin 2.5 mg, metformin hydrochloride 1000 mg), Segluromet 7.5/500 (ertugliflozin 7.5 mg, metformin hydrochloride 500 mg) and Segluromet 7.5/1000 (ertugliflozin 7.5 mg, metformin hydrochloride 1000 mg) in a pack size of 56.
- Tildrakizumab (rch) (Ilumya)** is a humanised IgG1/κ monoclonal antibody that specifically binds to the p19 protein subunit of the interleukin 23 (IL-23) cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine composed of 2 subunits (IL-23p19 and IL-12/23p40), that is involved in inflammatory and immune responses. Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Ilumya is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis. Ilumya is contraindicated with clinically important active infection (e.g. active tuberculosis). Ilumya solution for injection (single use prefilled syringe) contains tildrakizumab 100 mg/1 mL and is available in a pack size of 1.

## New Indications

- Nivolumab (Opdivo)** as monotherapy is now indicated for the treatment of hepatocellular carcinoma after prior sorafenib therapy. This indication is approved based on objective response rate and duration of response in a single arm study. An improvement in survival or disease related symptoms has not been established.
- Normal immunoglobulin (human) 20% (20 g/100 mL) (Hizentra)** is now indicated for immunomodulatory therapy in chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilisation with intravenous immunoglobulin.
- Pertuzumab (Perjeta)** is now indicated in combination with trastuzumab and chemotherapy for: early stage (either > 2 cm in diameter or node positive) breast cancer as part of a complete treatment regimen for early breast cancer; the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.

## New Contraindications

- Atazanavir (Reyataz)** is now contraindicated with concomitant lurasidone; glecaprevir/pibrentasvir (co-administration may result in increased ALT elevations due to an increase in glecaprevir and pibrentasvir plasma concentrations).
- Ropivacaine hydrochloride/fentanyl citrate (Naropin 0.2% with Fentanyl)** is now contraindicated in patients with a history of myasthenia gravis, after operative interventions in the biliary tract, and in children below the age of 12 years.

- **Sitagliptin phosphate monohydrate/metformin hydrochloride (Janumet, Janumet XR)** is now contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m<sup>2</sup>).
- **Vildagliptin/metformin hydrochloride (Galvumet)** is now contraindicated in patients with severe renal impairment (GFR < 30 mL/min).

*This list is a summary of only some of the changes that have occurred over the last month.  
Before prescribing, always refer to the full product information.*